Company Overview and News

to your dashboard

Headline News

The Top 10 Value Stocks in the S&P 500

1h investorplace
“Value will have its day in the sun.” That’s what John Buckingham, a veteran value investor and chief investment officer at AFAM Capital Asset Management, recently told Kiplinger in an interview. (264-0)

Gilead Collaborates with Pfizer for Yescarta Combo Study

1h zacks
Gilead Sciences’ (GILD - Free Report) subsidiary Kite announced that it has entered into a collaboration with Pfizer, Inc. (PFE - Free Report) to evaluate a combination of its newly approved CAR-T therapy Yescarta (axicabtagene ciloleucel) and Pfizer's utomilumab, a 4-1BB agonist, for refractory large B-cell lymphoma. (85-0)

Juno Therapeutics: What The Celgene Potential Acquisition Foretells

5h seekingalpha
It's prudent to take some profits while keeping the rest of one's shares for further upsides. (120-0)

The Passive/Aggressive Portfolio

7h seekingalpha
What if you want to be a little more aggressive with your investment strategy, say twice as aggressive? What if markets don’t deliver any year on year change? Then you need a little more pizzazz in your portfolio, and some extra leverage to earn your crust of bread and secure your retirement. It turns out that I have just the solution for you. This would be my “Passive/Aggressive Portfolio”. I call it passive in that you just purchase these positions and leave them alone and not trade them. (387-0)

Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive

10h investorplace
Celgene Corp. (NASDAQ:CELG), best known for the psoriasis medicine Otezla and a number of cancer drugs, like Revlimid and Vidaza, sent the stock of Juno Therapeutics Inc. (NASDAQ:JUNO) up 55% on Jan. 17 when it was reported to be buying it. An acquisition probably won’t change a lot for CELG stock. (81-0)

Bellicum Pharmaceuticals: CAR-T Play With Catalysts In 2018

14h seekingalpha
The acquisition of Cell Design Labs by Gilead is proof that preclinical assets in the CAR-T space hold value. (98-1)

Juno Hits 52-Week High on Celgene's Rumored Buyout Interest

2018-01-18 zacks
Shares of Juno Therapeutics, Inc. (JUNO - Free Report) hit a new 52-week high of $70 on Jan 17 and eventually closed at $69.25. The shares of the company hit the new high on reports that the company is being acquired by Celgene Corp. (CELG - Free Report) . Juno already has an agreement with Celgene for the global development and commercialization of immunotherapies. A potential acquisition of Juno, would help Celgene build and diversify its drug pipeline while building up future revenue streams. (91-0)

Cancer drugmaker Celgene may turn to Juno to avoid a looming disaster

2018-01-18 cnbc
A buyout of Juno Therapeutics could help Celgene diversify its drug portfolio as its No. 1 cancer treatment, which accounts for the bulk of its sales, approaches patent expiration, analysts say. (12-0)

3 Top-Ranked Drug Stocks That Are Broker Favorites

2018-01-18 investorplace
Pharma and biotech stocks made an impressive comeback in 2017 with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 18.7% and 11.8%, respectively. Investors appear to be more comfortable about the drug pricing scenario which was a major overhang in 2016. (85-0)

Merck & Co., Inc. Stock Could Still Soar Another 10% From Here

2018-01-18 investorplace
While Merck & Co., Inc. (NYSE:MRK) had gotten off to a modest pace to start the year, the last few trading sessions have been rather explosive. Specifically, on Jan. 16, MRK stock rocketed higher by about 6%. That move followed big gains in the prior few sessions leading up to Wednesday. All told, Merck stock is up more than 10% this year. (73-0)

BRIEF-Kite Announces Clinical Collaboration With Pfizer

2018-01-18 reuters

Biotech Forum Daily Digest For January 18th

2018-01-18 seekingalpha
There has been some volatile trading action in the biotech sector this week on fears of a government shutdown and potential M&A action. (145-0)

Analyzing The CAR-T Market: What Companies Have Performed Best And Will The Trend Continue In 2018?

2018-01-18 seekingalpha
The CAR-T market is red hot with 2 drug approvals, 1 major buyout (Kite) and a second potential major buyout (Juno) occurring in the last 6 months. (80-0)

Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA

2018-01-18 zacks
Novartis AG‘s (NVS - Free Report) supplemental Biologics License Application (sBLA) for Kymriah suspension for intravenous infusion, for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are ineligible for or relapse after autologous stem cell transplant (ASCT) has been accepted by the FDA for Priority Review. (91-0)

No Reason To Rush Into Juno Therapeutics Inc Stock After This Big Pop

2018-01-18 investorplace
Juno Therapeutics Inc (NASDAQ:JUNO) stock is up about 50% after the Wall Street Journal reported on Tuesday that biotech giant Celgene Corporation (NASDAQ:CELG) is in talks to buy the company. (81-0)

CUSIP: 375558103